Diabetic cardiomyopathy is associated with significant morbidity and mortality. It is
considered as a cardiac muscle disorder secondary to diabetes mellitus (DM). Certain studies
show the clinical benefit of SGLT-s inhibitors on reducing cardiovascular outcomes amongst
patients with type II DM that go beyond the correction of hyperglycemic perse. Thus an
observational imaging study is proposed to identify mechanistic insights of the drug group
over cardiovascular events.